Volume 32, Issue 5 (August 2021)                   Studies in Medical Sciences 2021, 32(5): 335-341 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

URL: http://umj.umsu.ac.ir/article-1-5499-en.html
Assistant professor pediatric hematologist and oncologist, Urmia University of Medical, Urmia, Iran (Correspondin Author) , mehranxnoroozi@gmail.com
Abstract:   (1869 Views)
Background & Aims: The present study aimed to compare the relationship between Procalcitonin and CRP with a prognosis of fever and neutropenia in children with acute lymphoblastic leukemia.
Materials & Methods: In this descriptive-analytical study, patients with fever and neutropenia who underwent chemotherapy were included. Duration of fever, length of hospital stay, mortality rate, Procalcitonin and CRP levels, and other patient information were included in the checklist and analyzed.
Results: In this study, 31 patients with fever and neutropenia were enrolled. The results showed that subjects with high procalcitonin levels had a longer duration of fever and hospitalization than those with lower levels of Procalcitonin. A statistically significant level was also obtained. The results of our study showed that there is a significant relationship between the level of Procalcitonin and sepsis (p = 0.001); however, the CRP level was not significantly correlated (p = 0.372).
Conclusion: Procalcitonin might be an adjunctive biomarker in identifying severity of disease, duration of antimicrobial therapy and choosing the right antibiotic for cancer patients with fever and neutropenia. Procalcitonin-guided algorithm may limit the duration of antibiotics, reduce adverse events, and prevent the emergence of antimicrobial resistance.
Full-Text [PDF 501 kb]   (690 Downloads)    

1. Südhoff T, Giagounidis A, Karthaus M. Evaluation of neutropenic fever: value of serum and plasma parameters in clinical practice. Chemotherapy 2000;46(2):77-85. [DOI:10.1159/000007259] [PMID]
2. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002:730-51. [DOI:10.1086/339215] [PMID]
3. Póvoa P, Souza-Dantas VC, Soares M, Salluh JI. C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia. Crit Care 2011;15(3): R129. [DOI:10.1186/cc10242] [PMID] [PMCID]
4. Buyukberber N, Buyukberber S, Sevinc A, Camci C. Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients. Med Oncol 2009;26(1):55-61. [DOI:10.1007/s12032-008-9081-z] [PMID]
5. Chaudhary N, Kosaraju K, Bhat K, Bairy I, Borker A. Significance of interleukin-6 (IL-6) and C-reactive protein (CRP) in children and young adults with febrile neutropenia during chemotherapy for cancer: a prospective study. J Pediatr Hematol Oncol 2012;34(8):617-23. [DOI:10.1097/MPH.0b013e3182677fc6] [PMID]
6. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79(6):1605-8. https://doi.org/10.1210/jc.79.6.1605 [DOI:10.1210/jcem.79.6.7989463] [PMID]
7. Von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J ClinMicrobiol Infect Dis 2004;23(7):539-44. [DOI:10.1007/s10096-004-1156-y] [PMID]
8. Reitman AJ, Pisk RM, Gates III JV, OzeranJD. Serialprocalcitonin levels to detect bacteremia in febrile neutropenia. Clinl Pediatr 2012;51(12):1175-83. [DOI:10.1177/0009922812460913] [PMID]
9. Hatzistilianou M, Rekliti A, Athanassiadou F, Catriu D. Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res 2010;59(5):339-47. [DOI:10.1007/s00011-009-0100-0] [PMID]
10. Secmeer G, Devrim I, Kara A, Ceyhan M, Cengiz B, Kutluk T, et al. Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia. J pediatr Hematol Oncol 2007;29(2):107-11. [DOI:10.1097/MPH.0b013e3180320b5b] [PMID]
11. Nasimfar A, Sadeghi E, Karamyyar M, Manesh LJ. Comparison of serum procalcitonin level with erythrocytes sedimentation rate, C-reactive protein, white blood cell count, and blood culture in the diagnosis of bacterial infections in patients hospitalized in Motahhari hospital of Urmia (2016). J Adv Pharm Technol Res 2018;9:318-9. [DOI:10.4103/japtr.JAPTR_319_18] [PMID] [PMCID]
12. Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin H, Guilbaud J. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341(8844):515-8. [DOI:10.1016/0140-6736(93)90277-N]
13. Haeusler GM, Carlesse F, Phillips RS. An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer. Pediatr Infect Dis J 2013;32(10):e390-6. [DOI:10.1097/INF.0b013e31829ae38d] [PMID]
14. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamarellou H. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 2001;32(12):1718-25 [DOI:10.1086/320744] [PMID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb